Simple item page
 

Selective androgen receptor modulator use and related adverse events including drug-induced liver injury: Analysis of suspected cases

cris.virtual.author-orcid0000-0002-0081-7585
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcidfa9a05b6-07fa-47e8-ae3d-8929da6881f3
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
dc.abstract.enPurpose Selective androgen receptor modulators (SARMs) have demonstrated agonist activity on the androgen receptor in various tissues, stimulating muscle mass growth and improving bone reconstruction. Despite being in clinical trials, none has been approved by the Food and Drug Administration (FDA) or European Medicines Agency for pharmacotherapy. Still, SARMs are very popular as performance-enhancing drugs. The FDA has issued warnings about the health risks associated with SARMs, but the long-term exposure and possible adverse events still need to be fully understood. This review aims to evaluate the adverse events associated with using SARMs by humans. Methods PubMed database was searched from September 16, 2022, to October 2, 2023. In total, 20 records were included in the final review. Data from preclinical and clinical studies supported the review. Results Since 2020, 20 reports of adverse events, most described as drug-induced liver injury associated with the use of SARM agonists, have been published. The main symptoms mentioned were cholestatic or hepatocellular liver injury and jaundice. Limited data are related to the dosages and purity of SARM supplements. Conclusion Promoting SARMs as an anabolic agent in combination with other performance-enhancing drugs poses a risk to users not only due to doping controls but also to health safety. The lack of quality control of consumed supplements makes it very difficult to assess the direct impact of SARMs on the liver and their potential hepatotoxic effects. Therefore, more detailed analyses are needed to determine the safety of using SARMs.
dc.affiliationWydział Medycyny Weterynaryjnej i Nauk o Zwierzętach
dc.affiliation.instituteKatedra Fizjologii, Biochemii i Biostruktury Zwierząt
dc.contributor.authorLeciejewska, Natalia
dc.contributor.authorJędrejko, Karol
dc.contributor.authorGómez-Renaud, Víctor M.
dc.contributor.authorManríquez-Núñez, Josué
dc.contributor.authorMuszyńska, Bożena
dc.contributor.authorPokrywka, Andrzej
dc.date.access2024-11-27
dc.date.accessioned2024-11-27T13:20:53Z
dc.date.available2024-11-27T13:20:53Z
dc.date.copyright2023-12-07
dc.date.issued2024
dc.description.abstract<jats:title>Abstract</jats:title><jats:sec> <jats:title>Purpose</jats:title> <jats:p>Selective androgen receptor modulators (SARMs) have demonstrated agonist activity on the androgen receptor in various tissues, stimulating muscle mass growth and improving bone reconstruction. Despite being in clinical trials, none has been approved by the Food and Drug Administration (FDA) or European Medicines Agency for pharmacotherapy. Still, SARMs are very popular as performance-enhancing drugs. The FDA has issued warnings about the health risks associated with SARMs, but the long-term exposure and possible adverse events still need to be fully understood. This review aims to evaluate the adverse events associated with using SARMs by humans.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>PubMed database was searched from September 16, 2022, to October 2, 2023. In total, 20 records were included in the final review. Data from preclinical and clinical studies supported the review.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>Since 2020, 20 reports of adverse events, most described as drug-induced liver injury associated with the use of SARM agonists, have been published. The main symptoms mentioned were cholestatic or hepatocellular liver injury and jaundice. Limited data are related to the dosages and purity of SARM supplements.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusion</jats:title> <jats:p>Promoting SARMs as an anabolic agent in combination with other performance-enhancing drugs poses a risk to users not only due to doping controls but also to health safety. The lack of quality control of consumed supplements makes it very difficult to assess the direct impact of SARMs on the liver and their potential hepatotoxic effects. Therefore, more detailed analyses are needed to determine the safety of using SARMs.</jats:p> </jats:sec>
dc.description.accesstimeat_publication
dc.description.bibliographyil., bibliogr.
dc.description.financepublication_nocost
dc.description.financecost0,00
dc.description.if2,4
dc.description.number2
dc.description.points100
dc.description.reviewreview
dc.description.versionfinal_published
dc.description.volume80
dc.identifier.doi10.1007/s00228-023-03592-3
dc.identifier.eissn1432-1041
dc.identifier.issn0031-6970
dc.identifier.urihttps://sciencerep.up.poznan.pl/handle/item/2116
dc.identifier.weblinkhttps://link.springer.com/article/10.1007/s00228-023-03592-3
dc.languageen
dc.relation.ispartofEuropean Journal of Clinical Pharmacology
dc.relation.pages185-202
dc.relation.projectSARMs jako modulatory funkcji metabolicznych i stresu oksydacyjnego tkanki tłuszczowej i serca w szczurzym modelu otyłości – badania in vitro i in vivo
dc.rightsCC-BY
dc.sciencecloudsend
dc.share.typeOTHER
dc.subject.enSelective androgen receptor modulators
dc.subject.enUnauthorized ingredients
dc.subject.enUnapproved pharmaceuticals
dc.subject.enDietary supplements
dc.subject.enSafety
dc.subject.enAdverse events
dc.subject.enLiver injury
dc.subtypeReviewArticle
dc.titleSelective androgen receptor modulator use and related adverse events including drug-induced liver injury: Analysis of suspected cases
dc.typeJournalArticle
dspace.entity.typePublication
oaire.citation.issue2
oaire.citation.volume80